Pure Global AI
NCT06408961Recruiting

EVOC - EVs in Obesity and Cardiometabolic Disease

Extracellular Vesicle Signaling in Obesity and Cardiometabolic Disease (EVOC)
Massachusetts General HospitalClinicalTrials.gov
Verified
Study focus
Disease/Condition
Cardiovascular Diseases
Study type
Observational
Sponsor & location
Primary sponsor
Massachusetts General Hospital
Location
Boston, United States of America
Timeline & enrollment
Phase
N/A
Start date
Jan 05, 2023
End date
Jun 30, 2026
Enrollment
80 participants
Primary outcome

What are the contents inside of fat (adipose) tissue derived Extracellular Vesicles (EVs)?,How does the contents of Extracellular Vesicles (EVs) impact cardiac and liver function?,Are changes in Extracellular Vesicle (EV) content related to cardiac function and adiposity with weight loss?

Summary

The goal of this observational study is to research the impact of molecular signals from the
 heart, liver and fat tissue on cardiovascular disease risk, and the presentation of Type II
 Diabetes and diseases that affect the heart, blood vessels and metabolism (Cardiometabolic
 Disease). Specifically, the focus is on the content and function of Extracellular Vesicles
 (EVs), small sacs released from a cell's surface that contain important molecular cargo. The
 main questions it aims to answer are:
 
 1. What molecular cargo do adipose-tissue EVs carry?
 
 2. How do these cargo impact cardiac and hepatic function?
 
 3. Are changes in EV content related to cardiac function and adiposity with weight loss?
 
 Tissue samples from fat tissue and blood samples will be collected from patients receiving
 bariatric weight loss surgery.

ICD-10 classifications
Cardiovascular disease, unspecifiedHypertensive heart diseaseOther ill-defined heart diseasesHeart disease, unspecifiedObservation for other suspected cardiovascular diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06408961
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06408961 through Pure Global AI's free database. This phase not specified trial is sponsored by Massachusetts General Hospital and is currently Recruiting. The study focuses on Cardiovascular Diseases. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.